Mark Lotter will resign as chief executive officer of SciClone's Shanghai Operations at the end of the year with plans to relocate to London to spend more time with his family. Mr. Lotter will also resign his position as a director of the company. The company began a formal search for a replacement. SciClone’s chief executive officer, Friedhelm Blobel, will work with Mr. Lotter and the management team to help ensure a smooth transition.
Dr. Blobel commented, "The SciClone board of directors joins me in expressing our appreciation to Mark for his many contributions to our Company's success following the acquisition of NovaMed in April 2011. As NovaMed's founder, Mark successfully grew this promising company into a well-respected specialty pharmaceutical company in China with a valuable product portfolio and product pipeline. All of us have enjoyed working in partnership with Mark on the successful integration of NovaMed into SciClone and on helping our combined Company to strengthen its standing in the top echelon of China pharmaceutical companies. Mark has had a long and productive career as a pharmaceutical executive, and we are confident that his talents and experience will serve him well in his future endeavors."
Mr. Lotter added, "I would like to thank all involved for their support in building what I believe has become the leading China specialty pharmaceutical company. SciClone today has a strong and experienced China management team, including seasoned general managers of our three business units, a strong portfolio of products and key strategic collaborations. I remain confident that SciClone will grow even stronger and continue to build its position in China. While my decision to leave will enable me to spend more time with my family, I am fully committed to facilitating a smooth transition process over the next few months."